Compare TG Therapeutics Inc (TGTX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Exxon Mobil Corporation — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Exxon Mobil Corporation trades at $151.79 (market cap $614.94B). The key difference: Exxon Mobil Corporation is far larger — about 74.4× TG Therapeutics Inc's market cap, and Exxon Mobil Corporation pays a 2.78% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | XOM | |
|---|---|---|
Market Cap | $8.26B | $614.94B |
Sector | Health | Energy |
52-Week High | $59.06 | $171.52 |
52-Week Low | $26.39 | $105.83 |
Enterprise Value | $8.50B | $654.17B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
ExxonMobil (XOM) trades at $147.39, up 0.99% today, with a bullish technical signal from moving averages and oscillators. The stock has beaten earnings estimates for the last three quarters, though revenue and net income have trended lower since 2022. Analyst consensus is a buy with a $169.78 price target, and recent news highlights the company's Permian Basin advantage and potential oil price spikes.
XOM offers value through strong cash flow and a robust balance sheet, but faces headwinds from declining profitability and net cash outflows. Investment appeal hinges on oil price stability and execution in key growth areas, while risks include volatile energy markets and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
